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Episode 45: Watchful Waiting 
Chris Dall: [00:00:05] Hello and welcome to the Osterholm Update: covid-19, a weekly 
podcast on the covid-19 pandemic with Dr. Michael Osterholm. Dr. Osterholm is an 
internationally recognized medical detective and director of the Center for Infectious 
Disease Research and Policy, or CIDRAP, at the University of Minnesota. In this 
podcast, Dr. Osterholm will draw on more than 45 years of experience investigating 
infectious disease outbreaks to provide straight talk on the covid-19 pandemic. I'm Chris 
Dall, reporter for CIDRAP News, and I'm your host for these conversations. 
 
Chris Dall: [00:00:42] Earlier this week, the United States passed a pandemic 
milestone that would have seemed unimaginable a year ago- five hundred thousand 
deaths. More Americans died in one year of the covid-19 pandemic than in two world 
wars and the Vietnam War combined. The immensity of that number and all the people 
who have been impacted by those deaths is staggering. "The people we lost were 
extraordinary," President Joe Biden said in the ceremony to mark the grim milestone. 
We have to resist becoming numb to the sorrow. But while the nation processes the 
massive loss of life over the past year, more and more questions are being raised about 
what the coming year will look like. Covid-19 cases continue to decline in the US and 
around the globe, and more people are getting vaccinated. But coronavirus variants 
continue to spread and are threatening to reverse those gains. How do public health 
officials balance the public's desire to return to normal, especially among those who 
have been vaccinated, with the need to remain vigilant against another surge? On this 
February twenty fifth episode of the Osterholm Update, we'll discuss the growing 
questions about how we define the new normal and what people can do and can't do 
once they're vaccinated and how the variance will affect that equation. We'll also talk 
about the impact of covid-19 vaccines and discuss a new CIDRAP viewpoint on the US 
vaccine deployment in anticipation of a B117, and we'll highlight another pandemic act 
of kindness. But first, we'll begin with Dr. Osterholm's welcome and dedication. 
 
Michael Osterholm: [00:02:06] Thank you, Chris. Welcome, everyone, to another 
edition of the Osterholm Update. So good to have you with us. We appreciate very 
much the time that you spend listening to this podcast and for sharing all that you do 
with us about the podcast, about what goes on in your lives, your questions, your 
concerns, your ideas, your hopes, your dreams, thank you so very, very much. This is 
very meaningful to all of us. And I tell you that there are weeks that we can use your 
comments more than you know to help us get through that week. This is one of those 
weeks. I don't know how to even begin to try to put some kind of a human sense around 
the number of five hundred thousand deaths. We've talked about this time and time 
again about numbers are not people. People are brothers and sisters, father, fathers 
and mothers, aunts and uncles, grandpa and grandmas, colleagues. That we must 
never forget. But the epidemiologist in me, looking at how do I try to bring some sense 
of the significance of this number to all those I didn't know, to all those fathers and 
mothers and grandfathers and grandmothers. I thought about it this way. If you take 
those five hundred thousand very special individuals by name, and I take three seconds 
to say their name with respect, I can say 20 names in one minute. But it would take me 
four hundred and seventeen hours or 17.4 says, twenty four hours a day to read each 
one of those names. Think about that. Four hundred and seventeen hours reading one 
name every three seconds. That is the breadth, the depth and the pain that this 
pandemic has caused us. So I hope we focus on that today, focus on the names, say 
their names, say what they meant to you, see their faces, see the faces of their loved 
ones they left behind. That's what we have to remember today as we start this podcast, 
but it's also a time where we have to move forward, we have to remember, but we also 
have to look to that future. And I'm very happy to report to you today from the great city 
of Minneapolis that on February 25th, there will be exactly 11 hours of sunlight. We've 
gained twenty one minutes since last week. We've gained now two hours and 14 
minutes since that December 21st winter solstice. And each week, the numbers are 
going to get bigger faster as we get closer and closer to spring and into the summer. So 
that's what we have to also remember as we go forward, remembering the names and 
celebrating the light. This has been a tough week in the United States for those living in 
the southern states, particularly in the state of Texas. It has been a tragedy to watch 
what's happened with the weather, the number of people who have had a devastating 
impact in their lives with frozen pipes, lack of electricity, frostbite, deaths due to 
hypothermia, damage to their properties that have been so substantial. So this week I 
dedicate this podcast to all of you who have been living through the horrible, horrible 
situation of the weather in Texas and the other adjoining southern states. Our thoughts 
are with you. We wish you well and know that recovery will not happen overnight. But 
let's get on with recovery, just like we need to do that with all of our lives relative to this 
pandemic. On our way to recovery. We've titled this week's episode Watchful Waiting. 
That's where we are right now. Yes, we are tending to the business of getting people 
vaccinated and we're urging the public that we still must follow the risk reduction 
measures we've been advocating for the past year. We're also watching and waiting. 
And we're watching and we're waiting. Still feeling that lingering fear of what we've been 
through, but what may still lay ahead. We're hoping the main thrust of the pandemic in 
the US could very well be behind us as vaccinations continue here, oh do we. But we 
fear what could develop in the next month or two, which is a whole new surge related to 
the new variant B117. As you know, it first took off in the U.K. just a few months ago. 
Last month, we established the metaphor in this podcast of an approaching hurricane of 
Category five strength. And we've kept with it because I believe it so aptly fits our 
current situation. We're on that beach again. We've got hit by some severe weather in 
the weeks gone by, but the clouds have parted. It's sunny, no clouds, only a slight 
breeze, everything looks great. And after a long period of sheltering, we've earned the 
right to come out and catch our breath, at least for a little bit. But not completely. No, not 
completely. The hurricane warnings still in place, everyone. And enough of the science 
is telling us that the real hurricane is continuing to approach, that we have to take this 
threat very, very seriously. It's now just one hundred and fifty miles away, a lot closer 
than it was a few weeks ago. We need to do two things. One, catch our breath a bit for 
the sake of our mental health. Oh, we need to do that. But we also cannot let our guard 
down. So let's talk about the first bit, our mental health. Yes, the pandemic has been a 
nightmare, but now is the time for us to retain our sense of humanity. The pandemic 
doesn't have to spell an end to life as we knew it, we just need to figure out how to live 
with this virus, which is something I'll get into today. We have died by this virus. We 
have somewhat lived with this virus today. How do we really live with this virus moving 
forward? A critical item in today's episode is the news that we released Tuesday from 
CIDRAP regarding how we must prepare for that possible hurricane. This is our seventh 
major viewpoint report since the start of the pandemic. And quite possibly, it is our most 
important as we continue at CIDRAP to do our best to be a beacon of reliable 
information in a crazy storm of information of the past year. I'll talk more about our 
report later when we address the issue of delaying the second dose, we may save more 
lives in the weeks ahead. But now is the time for us to remember all those who died in 
this pandemic. And those who still might. We watch and we prepare for tomorrow with 
both caution and hope, and all I can say is nuts to this virus. 
 
Chris Dall: [00:09:40] Mike, as we've been discussing in recent weeks, covid-19 cases 
and hospitalizations continue their steady decline here in the United States and around 
the world, with the exception of a few hotspots. I know I've asked you this question 
several times, but do you have any more insight into what's behind this decline? 
 
Michael Osterholm: [00:09:57] First of all, it's really important to validate that this 
decline is real. It's real. I'm not sure how reliable the numbers are these days relative to 
the actual number of cases. I've already laid this out before in terms of acute cases, 
infections reported through testing, we've got several factors taking place. We're 
hearing of more and more situations where state and local health departments, even 
within some medical centers, people are being diverted from testing programs to 
vaccination programs which in of themselves challenge how many people get tested. 
Second of all, we're hearing of people more often now wanting to get tested if they have 
mild symptoms because they don't want to be put in quarantine. They don't want to 
somehow be isolated relative to their infection. I can understand that personally. 
Obviously, that's a challenge for us to know what the numbers really mean. And then 
you have events, like I just mentioned, with regard to the weather in Texas. No doubt 
there has been great challenges in a state like Texas getting accurate testing results out 
of there for the past seven to 10 days. But with that, let me just be clear, this downward 
trend of cases is real. It's rather dramatic, but it still is at a baseline that is higher than 
the peaks we had in April and July. Today, as I talk to you about the cases, we are right 
there at the very, very peak of what we thought was a house on fire event in July of this 
past year. So we have to continue to remember that importance of shifting baselines 
and how we somehow become willing to accept, oh, we're way, way down when in fact 
we are at a high relative to what it was just six months ago. Now, one of the areas that I 
am looking at very carefully in terms of trying to understand what's happening with the 
epidemiology of covid-19 in the United States is not actual cases reported. I'm looking at 
hospitalizations and deaths. Those you don't really have an alternative. I'm not going to 
go to the hospital. I don't want to be tested. I'm not going to basically have the testing 
capability available. But now I need to be in the emergency room to get into the hospital. 
There you really have less of a filtering device going on in the community and you're 
more likely to really pick up that tip of the iceberg that then represents what's 
underneath the iceberg. The challenge with that is, of course, it's delayed. It's a lagging 
indicator. When we see a turnaround in the number of individuals hospitalized or 
deaths, that's often two to four weeks after the cases have occurred in themselves. So I 
worry that right now we don't have a precise way of understanding what's going on, 
more so than any time since the pandemic began, except for those early days when we 
had no testing at all. So I think this is a challenge. What does it mean to see this big 
drop in cases? I've already talked about shifting baselines up and down, up and down. 
And sometimes when we see this downward trend or upward trend, we act as if it hadn't 
happened before and this is all brand new. This downward trend has happened three 
different times so far in this pandemic here in the United States. But what could be 
responsible for this rather sizable drop? And I've seen reports from many different so-
called experts, they surely have training in various aspects of medicine and public 
health, ascribe many different reasons for why this has happened. But I am not 
convinced that they are right on any of them. And this is where the humility comes in. 
Please understand, take my comments in that same light. I have to tell you,challenge 
what I'm saying right now. But I hear over and over again it's seasonality. There are no 
data to support seasonality whatsoever. Why do I say that? Because look what's 
happening in the Southern Hemisphere countries also. And remember, the big decrease 
we're seeing in cases right now has largely come from the substantial burst in cases 
that occurred in the southern states in January. But those are the same states that were 
on fire in July. So if you're going to use humidity or temperature or whatever, there's just 
no consistency there whatsoever at all. When you see the southern hemisphere light up 
right now or the case numbers drop, that, too, would suggest, well, there isn't a northern 
southern hemisphere difference like we might see with influenza. And finally, let me just 
continue to remind you of what we see with influenza pandemics, and while I 
understand this is a coronavirus, I think there's lessons to be learned here. I've been 
studying pandemics for the last twenty five years of my life, trying to understand them. 
And now I'm sitting in the middle of one and I'm trying to bring together all that 
information that over the years I had the opportunity to review and understand. And as I 
pointed out in a previous podcast, there have been 11 influenza pandemics in the last 
two hundred and fifty years. Three started in our winter, three started in our spring, two 
started in our summer, and three started in our fall. If you look at every one of those for 
which we have any kind of real data, you can see that there was this initial wave or 
surge of cases, a peak that occurred at the time of the first movement of the virus in 
humans. And then that peak would just disappear, no human mitigation strategies, 
nobody was vaccinating, nothing. Why did that happen? Why did it just disappear? 
Look, no further than two thousand and nine with H1N1 when it appeared in March in 
Mexico, peaked in late April, decreased dramatically in May, was absent most of the 
summer, took off in the late August time period in the southern states when it was the 
hottest it had been all year. The peak climbed in North America through mid to late 
September and dropped off precipitously in October, long before a vaccine arrived. 
Now, that's not seasonality, there was something else driving that and we have seen 
that kind of picture over and over again. The difference is with influenza, it then 
becomes a seasonal virus, sometimes after two or three years. It literally took 1918 
H1N1 almost two years to become a seasonal virus from its up and down surges. I don't 
know what this means for the coronavirus, but I'm struck by the fact that there is 
something else going on. There is this viral interference. We are seeing almost no viral 
respiratory pathogens today in our pediatric population. If you go look at our 
hospitalization rates right now for kids, it is dramatically below what we've seen in recent 
years. If you look at influenza activity, same thing, way below what we would normally 
expect to see. Now, you can't say it's just because of mitigation, because, frankly, we 
haven't done all that well with mitigation with covid-19. Look at all the cases we've had. 
So if, in fact, it were just that, you would expect to see at least some activity with flu and 
with the other viral respiratory pathogens. So I think there is something going on here 
that Mother Nature is doing across a diverse area of the world that we just don't 
understand. And we have to acknowledge that. I just want to add one additional caveat. 
Some could take what I just said, meaning that, in fact, none of the mitigation strategies 
we're doing in public health make a difference because Mother Nature is doing it all on 
her own. And I think the data are compelling from events like 1918, from even here with 
covid-19 is that when we see these surges and you try to put into place mitigation 
strategies for distancing, for masking, to limit transmission, et cetera, they make a 
difference in terms of basically smoothing off that curve or shaving off that curve, which 
is a huge issue that is important. No one can take my comments as a reason to say that 
we shouldn't be doing mitigation when in fact we see these cases in our communities. 
But at the same time, let's just acknowledge with some humility, as I've said over and 
over again, we're not driving this tiger, we're riding it. And only when we have the world 
vaccinated and we can deal with the virus that way, then will I say we're driving it and 
riding it. In the meantime, I don't know why these surges are up and down. I just know 
that because I don't know why I surely can't give you any assurance that they're not 
going to happen again. Other reasons that people have raised for this curve dropping so 
precipitously is vaccination. Well, right now, only six percent of the US population has 
received two doses of the vaccine. Another 13 percent have received one dose. Those 
are hardly large enough numbers to suggest that they could have made this curve do 
what it did. Not saying it hasn't impacted on it, I think in long term care, we're going to 
start seeing some really immediate impact of reduced deaths in long term care. But it's 
not vaccination. And again, risk mitigation, let me just be really clear, I know people 
want to say how compliant we are right now, how people are masking. We are seeing 
the single greatest change in risk mitigation recommendations and oversight that we've 
had since the pandemic began. Look what's happening right now, state after state 
restrictions are being lifted, restaurants are opening, bars are opening, gymnasiums are 
opening, funerals are now able to be at any number of people wanting to come, 
weddings. I can go through the laundry list of things that are happening. And I 
understand why, people want to get back to what they once had. And governors and 
mayors are caught in that vice of saying, "Well, I got to open up my economy." And so if 
you look at seasonality, nope. Risk mitigation as we're doing it, nope. Vaccination, nope. 
The only thing I have left is the unknown. And again, I come back to that and just say 
that that's all the more reason why I'm concerned about what could happen in the 
future, because as much as we think we know what this virus is going to do, we're in a 
chess match with it right now, and it's seeming to make moves that we've never seen 
before. 
 
Chris Dall: [00:20:44] So what are you seeing on the variant front and specifically, do 
you still see the B117 variant becoming the dominant virus in the US by the end of 
March? 
 
Michael Osterholm: [00:20:53] Well, let me remind all the podcast listeners and some 
of you may be new that when we talk about variants, we're talking about what has been 
many, many, many different viruses going back to the very first days of their emergence 
in humans. These are viruses that have gone through one or more mutations that then 
they either survive within human to human transmission or they get outcompeted by 
other sars-cov-2 viruses. What we're really concerned about are those variants to do 
one of three things. They, number one, are more transmissible. In some cases 30 to 70 
percent more transmissible than previous viruses. Number two is they cause more 
severe illness, including hospitalization and deaths. And number three, they are able to 
evade the immune protection in an individual, either whether that arose through natural 
infection immunity or from vaccine related immunity. And those are what are really 
driving us today in terms of concern about what the variants can do. So the B117 
variant, and now unfortunately it's being named a subgroup variant, meaning that of 
Kent or that of Bristol. Kent being the old B117, Bristol being the new B117, where it has 
now picked up the mutation that is of concern to us as it relates to evading immune 
protection of the host. The variant that is the primary one in England, and what is 
circulating widely here in the United States is in fact the B117 Kent that does not have 
that mutation change that would allow it to escape the immune protection of either 
vaccination or natural disease. So where are we at in the United States? We're still 
flying pretty blind. This is a real challenge. As of February 21st, CDC is now reporting 
sixteen hundred and sixty one cases of B117 in forty four states. The Helix Dashboard, 
a dashboard of a company that does a great deal of sequencing reports that 14 percent 
of positive samples in Florida are B117 and 8 percent in California are B117. However, 
the California data lag by almost two weeks. If we look at Florida cases, there have 
been declining through January and February, although there may be a signal flattening 
the past few days. That would not be surprising, even with B117 present in that if you 
look at the European countries where this has taken off, there were actually weeks 
where B117 was beginning to circulate where case numbers continued to drop before 
they suddenly surged. As I mentioned, the Bristol variant, which is the B117 variant that 
also has this 484K mutation the one we talked about evading immune protection has 
now been reported in the United States. The first case was reported to CDC on 
February 17th. But it still is basically a very, very rare finding. The UK now has reported 
twenty one cases of this variant, but the vast majority remain the Kent variant, the the 
one without that mutation. Just to summarize, in the United States, we are seeing B117 
continuing to spread geographically, I believe it's in all 50 states now, it's just a matter 
we haven't been able to find it because of the lack of sampling. And in some areas, 
such as in Florida and California, the numbers are increasing at that rate of doubling 
roughly every 10 days. This is the challenge we have before us. If you look at what's 
happened in the other countries of Europe and the Middle East, I think it's very 
instructive what might happen here. So let me just spend a moment on that to give a 
sense of what we could see happening here. If you look in the United Kingdom right 
now, more than 90 percent of the samples being sequenced there are B117. Ninety 
percent. As you know, the UK is still in a lock down. Schools and non-essential 
businesses are still closed. Daily cases from before the holidays have dropped from 
sixty thousand per day to now about eleven thousand per day. Seems to be stabilized 
the past few days. That's a big drop, but it's literally taken them a month of a total 
lockdown and the additional vaccination to get them to this point. Hospitalizations are 
still declining, but they remain high at about eighteen thousand, which is just slightly 
below the UK spring peak last year of twenty one thousand and is still above their 
November peak, which was the first one they had of seventeen thousand. They are 
starting to discuss cautious step by step reopenings, starting with the reopening of 
primary and secondary schools on March 8th. Again reminding you they've been closed, 
they've been closed since mid-December. So it gives you a sense of what this is really 
all about and what's happening in the United Kingdom to deal with this. If one looks at 
Denmark now, over 50 percent of the cases in Denmark are B117. The country remains 
largely in a lockdown, although recently they've reopened daycares and elementary 
schools. Why is that important? Well, it's important if one looks at the fact that they've 
reported outbreaks in at least two schools, sixty nine total cases in eight day care 
facilities, including 20 total cases after they've reopened. This is a challenge we talked 
about before, will B117 even cause more transmission to potentially occur in a school 
that didn't happen before? Denmark is still considering further reopening beginning 
March 1st, which they would likely involve more school reopenings and some shops 
with restricted capacity. Many of the health officials there have said publicly they're very 
wary of reopening warning of an April wave if reopenings aren't literally limited. Now, 
they've been struggling with this, too, for weeks and weeks. Cases in Germany are now 
down to about seven thousand five hundred today from their winter peak of twenty six 
thousand a day. But they're showing now new signs of increase. More than twenty five 
percent of the cases in Germany are B117, and that number is increasing. A number of 
health officials have been cited in the media as saying that B117 is spreading rapidly 
and now they're doubling every week. And non-essential businesses are still closed in 
Germany and has limited private gatherings to a max of just two households. Some 
officials are feeling it's too early to lighten these restrictions. And you can see again how 
they're struggling. Daily cases are rising in the Czech Republic, about nine thousand 
five hundred new cases a day, although they haven't reached their peak recorded 
during the January peak. But now it's because what they're seeing is additional spread 
to B117. And they're attributing this turnaround where they had a peak, dropped, but 
coming back up again to this. The Netherlands daily cases are rising there. They're at 
four thousand, although they're still down from the December peak. And the 
Netherlands is still in a lockdown with non-essential businesses closed and gatherings 
restricted. And this is expected to be extended. They've also had shortage of hospital 
beds where they've actually had to move patients from the Netherlands to Germany for 
health care. The country is considering allowing students return to in person classes for 
a few hours each week and might allow some business to reopen. But this has been 
heavily debated. In British Columbia, the province is at a crossroads, as they're 
describing it. In which they've documented B117 in seven schools just this past 
weekend. The provincial officials have stated there's no need to implement changes to 
school reopening despite the recent cases. But that's been highly controversial. Cases 
there continue to grow in the province this past month. And recently, Newfoundland 
closed its schools in response to major upticks in cases there, largely B117. If you look 
at what happened there, they've had more cases in the last two weeks due to B117 than 
they'd had in the previous pandemic combined. So I just share all this with you about 
the B117 to say that's what we're looking at. That's what we think could very well be 
what would happen in the United States. And when I hear people say, well, it's not going 
to happen here, there is no one that has any information that would reliably tell us that. I 
think it's really a function of what can we learn from these countries. I didn't cover the 
issue with Israel, same problem there, etc.. Let me just say two last things quickly about 
the B1351 which is the variant from South Africa that we've worried about with regard to 
the ability to evade human immune protection. And the CDC is now reporting there are 
twenty two cases in 10 states here in the United States, far below that of what we've 
seen circulating for B117. Whether or not this will actually be driven here and actually 
compete against B117 is not clear. There is a recent paper in the Journal of the 
American Medical Association that discusses the B1351 driven outbreak in Zambia. And 
just this past week, The Washington Post carried a story about an outbreak in Tanzania, 
although officials there say they are still covid free, but it's due to a lack of testing. 
Finally, the last variant of concern that we've been talking about is the P1, the one from 
Brazil. And as of February twenty first, CDC still reports a very small number of cases, 
five cases in four states. We're still not getting a lot of information out of Brazil what's 
happening there, but this variant doesn't seem to be spreading. So I think this all comes 
back to one conclusion. It is about B117 and what it might do in the next five to 12 
weeks. And for any of us that don't take note of what's happened in Europe, what's 
happening in the Middle East right now, I'm concerned that we will get caught surprised 
if this virus continues to do in the United States what I think it will do. 
 
Chris Dall: [00:31:17] So let's talk about vaccines. First, there's some really interesting 
real world data coming out of Israel and the United Kingdom on the impact of the 
vaccines, both on symptomatic illness and on transmission. Also, as you noted, there's 
a new CIDRAP viewpoint out this week on reassessing the vaccine deployment strategy 
in the US in the face of the B117 surge that includes some notable names from the 
worlds of immunology and epidemiology. So, Mike, what is the data from Israel and the 
United Kingdom telling us and how does it relate to the viewpoint? 
 
Michael Osterholm: [00:31:47] Well, first of all, it was a really a very special 
opportunity to, again, work with colleagues from both inside of CIDRAP and outside of 
CIRAP to put this document together. The title of this report is Reassessing covid-19 
Vaccine Deployment in Anticipation of the United States B117 Surge: Stay the course or 
Pivot? My co-authors on this are Angela Ulrich and Cory Anderson, very valuable 
members of this Osterholm Update team, as well as Eric Topol, who many of you know 
from Scripps, Bruce Gellin from the Sabin Foundation, Ruth Berkelman, professor 
emeritus from the Rollins School of Public Health in Atlanta, Marc Lipsitch, who is from 
Harvard, and Kris Moore, our medical director here at CIDRAP. And this group has 
worked very hard at trying to pull together what are the data that we have in terms of 
what might happen with a B117 surge? If it does happen, what might it look like? And 
what are we currently doing with our vaccine programs? And we open the document 
with what I think is a very, very important quote. It's one that we should all take very 
seriously. And it comes from Secretary Colin Powell. Who said some years ago, 
"Generally, you should act somewhere between p40 and p70, as I call it. Sometime 
after you obtained 40 percent of all the information you're liable to get, start thinking in 
terms of making a decision. When you have about 70 percent of all the information, you 
probably ought to decide because you may lose an opportunity in losing time." And I 
think that's where we're sitting right now with this issue here. Do you believe that B117 
could possibly be a challenge here in the United States in the upcoming five to 12 
weeks, or do you not? And again, what are your data for each of those? I've already laid 
out where I believe it falls and what the potential is for this resurgence. Let me just say 
that what we did is we came up with a series of pressing issues in this document and 
tried to provide as clearly as we could, a overview of where we're at and what we might 
consider. Number one pressing issue, the more transmissible sars-cov-2 B117 variant 
could lead to a significant surge in US cases in the next four to 12 weeks. If the B117 
surge overlaps with low vaccine coverage, it will cause immense strain, an already 
burdened health care system threatening the level and quality of care available to our 
patients. The second pressing point, the immediate goal of public health agencies 
should be to reduce hospitalizations and deaths, as well as maintain the ability of the 
health care system to provide adequate health care services and minimize preventable 
suffering and deaths. Number three, age is the strongest risk factor for severe disease, 
hospitalization and death from covid-19. In the event of a case surge, the vast majority 
of hospitalizations and deaths would occur in adults sixty five years of age and older. 
The fourth pressing issue, compared to when the messenger RNA vaccines were 
authorized, we now have more complete data regarding the B117 variants, including 
how they led to surges in other countries and they're currently rapidly increasing 
incidence in the US. Five, we have a short period to relieve the strain on the health care 
systems and save lives by strategically targeting vaccination to those at highest risk of 
hospitalization and death. So that was our overall thesis on this issue. Let me make it 
really clear that when we look at these issues, I have heard repeatedly, we have to 
follow the science. I think if anyone has been following the media the last several 
weeks, as I've been saying, there's a lot more information that can be gleaned that 
could be used. And you're seeing it get published now from England, from Israel, from 
even here in the United States, reanalysis of the previous studies. So for those who 
have been suggesting that whatever the FDA had in of by themselves weeks ago when 
they made a decision on emergency use authorization was the only data available, 
that's just simply not true. And we owe it to the public, we owe it to our colleagues to 
look at every piece of information we can. And just as we speak this week, more and 
more papers are coming out supporting the idea of what one dose versus two doses 
can be. So what we've come up with is really four primary activities that could support 
increased vaccination of those over 65 years of age, and that could therefore reduce the 
impact of a surge should it occur. All of these are contingent upon the fact that we do 
see sufficient data to support that a delayed second dose, delayed, I want to make that 
very clear. And we're not talking about delaying it months. We're talking about until we 
might get through a surge of B117, with my best professional judgment, would be no 
more than 10 to 12 weeks at most, as we've seen with other surges. So what are the 
four recommendations we're saying? Look at, look at this. Allocating the vaccine with 
people sixty five years of age or older given highest priority. We know that that is going 
to mean that those younger than sixty five will not have access that might otherwise 
have. And I understand the challenge with that. But if we're trying to keep the burden of 
health care service needs at a manageable level with a B117 surge, then that's where 
it's going to happen. Number two, deferring second doses of messenger RNA vaccines 
until after the surge. I'll talk about that more in the days ahead, but you're already 
seeing data coming forward from studies showing that there was quite good efficacy 
even after one dose. And let me be clear, I find it a little challenging when people say, 
"Well, we only have this much efficacy at one dose, but look what happened after two 
doses." As we're seeing with the AstraZeneca vaccine in Europe is if you didn't do a 
second dose, you still kept seeing first dose improvement over time, meaning that the 
second dose didn't just automatically abbreviate what was then beginning to be a 
declining improvement in efficacy with dose one. It actually is like growing corn. It took 
months to get it to grow. Well, an immune response takes weeks and weeks. And so I 
understand that the importance of the second dose, I'm not at all suggesting it doesn't 
happen, but it's not appropriate to say that you somehow got a different result with the 
second dose because of that second dose only. We don't know that with first dose we 
wouldn't see ninety five percent protection over time. Then we also said authorize the 
use of half dose regimens for the Moderna vaccine. There's clear data that has come 
out showing that a 50 microgram dose, half of what is currently in the vaccines, resulted 
in a similar robust immune response and the correlates of protection compared to one 
hundred microgram dose. Imagine if we could have twice as much Moderna. And last 
but not least, the fourth recommendation we made was defer the second dose of an 
mRNA vaccine in people with confirmed covid-19 infections. More and more data has 
come forward supporting that a one dose may rapidly generate high levels of antibodies 
among individuals who previously had a confirmed infection. Why are we worried about 
at this point giving them a second dose within that three to four week period? So if we 
just looked at those, they very well could provide us with this cushion that we need in 
terms of the science. And let me tell you what we looked at in our report. We actually 
worked out five different scenarios. One where two doses were administered with 50 
percent of the supply given to those over sixty five. Right now, it's only about a third 
over age sixty five getting vaccinated, two thirds under the age sixty five. Imagine two 
doses administered with one hundred percent of supply given to sixty five years of age 
and older. A deferred second dose with 30 percent of the supply going to those sixty 
five years of age and older. The fourth one was a deferred second dose, with 50 
percent of the supply going to those sixty five years of age and older. And a deferred 
second dose with one hundred percent of supply given to sixty five years and older as 
our fifth final one. Let me just tell you that if you look at if we keep doing what we're 
doing now and we don't see any measurable improvement in the amount of vaccine 
available, we could expect with a B117 surge, and we've laid out all the different criteria, 
factors you can adjust them however you want to look at this, but without changing 
anything right now, we could expect one hundred and sixty one thousand 
hospitalizations and fifty six thousand deaths with a B117 surge. Much of that in that 
over age sixty five age group. If you look at the strategy we talked about, strategy five, 
where basically we in fact administer vaccines as a single dose and prioritize sixty five 
year olds covering them, we could drop that one hundred and sixty one thousand 
hospitalizations to forty nine thousand hospitalizations and we could drop the number of 
deaths from sixty fifty six thousand to seventeen thousand. These are our mom and 
dads, our grandpa and grandmas, our brothers and our sisters, they're not just 
numbers. Now, if you don't agree with us and you think we're all wet, that's fine. But 
then come up with your own explanation, your own data. And this is a decision we need 
to make soon. And I know for the last month and a half I've been putting this out here 
and I recognize that that's not a welcomed discussion among many because they just 
want to stick with what we have. But now's the time for us in public health, I believe, to 
basically confront this idea that one, a B117 surge in the United States, I believe, is only 
becoming more of a potential reality. And I say potential reality every day. We're not 
seeing the B117s melt away. And we know that that will be particularly hard hit in the 
older age population. Right now our estimate is if we continue on the current track we're 
taking and we don't see a sizable increase of vaccine between now and the end of 
March, which we may get some towards the end of March, 30 million Americans sixty 
five years of age and older, out of fifty three million, 30 million will not have a drop of 
vaccine. Going into a surge, that's just wrong, that's wrong. So I think that this is really 
an important point. So our final recommendations on this is, we believe, an emergency 
meeting of VRBPAC, the FDA advisory group, and the ACIP, the CDC advisory group, 
should be convened to urgently review the existing data, epidemiology, virology, 
immunology, the modeling, all the data to determine how best to use the current vaccine 
supply and the supply that will become available in the coming months. I can only hope 
that suddenly somebody would say, "Oh, my, we're going to give you 10 million doses a 
day, not 1.7 million." That would help. This should include all published unpublished 
data available for all the vaccine clinical trials for vaccines authorized for emergency 
use by the FDA or vaccines that may be authorized in the next two to six weeks. No 
longer accept the fact we have to follow the science as code for we already looked at 
this once we're done looking at it, we don't have any new additional data. What I said 
weeks ago is now starting to actually become reality, that there were a lot of data out 
there that are now being published that we have available to us. Number two, we should 
optimize the current vaccine supply in preparation of a possible B117 surge. VRBPAC 
and ACIP should consider whether existing data support age-based allocation with the 
highest priority given to adults sixty five years of age and older, deferring second doses 
of mRNA vaccine to after the surge, and deferring the second dose of mRNA vaccines 
in individuals confirmed previous covid-19 infections and/or the authorization and the 
use of a half dose regimen for the Moderna vaccine. Number three, we believe if the 
data supports a change of the current authorizations or recommendations, the FDA 
should revise its authorization determination as soon as possible. And finally, a 
coordinated public communications campaign must be undertaken to provide clear and 
consistent messaging to the public regarding any change in the vaccine schedule or 
prioritization groups due to the deferment of second doses of vaccines. I understand 
this would be controversial. There'll be some saying, "Wait a minute, I'm not getting my 
dose now that I thought I could get." We're not telling anyone who's already had one 
dose they can't get their second dose. We're saying only new people enrolled going 
forward would not get their second dose until after the surge. And I think that that's in 
the sense of utilitarian model of trying to look at how to do the most good for the most 
people, I still believe that that's the case. I would close it by just using the example I 
used last week. I'm sitting across the table from my grandparents. Both of them have 
underlying health conditions. Both are in their late 70s. I have two doses of vaccine. Do 
I decide with them to give one dose to each day, or give two doses to one and none of 
the other? How do we decide? I believe the data clearly support right now we could do 
great benefit and give my grandpa and grandma a better chance of being around by 
giving them each one dose than to give two doses to one, which means you may very 
well not even get ill at all. But the other one could likely die if you got infected. So I hope 
that this adds some clarity. I know it's still a controversy. I know that we don't know if 
B117 is going to take off. I don't know that. But as Secretary Powell said, "We don't 
have the luxury of knowing all of that." But if we do wait and a surge does occur, it'll be 
far too late for us to react and respond. 
 
Chris Dall: [00:46:24] Now to the issue that I raised in the intro, we're seeing a growing 
number of people who have received both doses of the vaccine and want to know if 
they still have to follow covid-19 precautions or how strictly they need to follow them. So 
here's a listener email we received that I think captures what many people want to 
know. Michael writes, "My wife, Gail, and I have really enjoyed your informative 
podcasts and updates. I was wondering if you would address how we should act after 
we get both of our covid shots and then wait the two to three weeks for it to build 
immunity. Is it safe to fly across the country to visit family members, some of whom 
have been vaccinated and some who have not? Can we go to restaurants and stores? 
We would still wear masks in public and distance as best we can. We're both around 70 
years old and have had our first covid shots. We're just wondering how to act in the 
future." So Mike, do we have any answers for these types of questions yet, or do we 
need more information on whether the vaccines can reduce transmission? 
 
Michael Osterholm: [00:47:19] For a number of months, I have been raising the issue 
right here on this podcast that we have to figure out how to learn to live with this virus. 
And what I mean by that is, is that we won't have all the perfect answers. We won't have 
all the perfect protection. But I don't believe society will continue to wear masks, 
distance themselves, refuse not to travel. It's just not going to happen. And what we 
have to understand has public health professionals, our job is to protect the public, give 
them the best science we have. And right now we don't have the science at our 
fingertips that says if you get two doses, you're not only protected ninety five percent of 
the time, but you don't transmit to others. And we keep kind of, in a sense, getting 
behind that message of we don't know if you don't get an asymptomatic infection and 
transmit to others. I think at some point we're going to have to accept the fact that once 
you've been vaccinated and I believe right now, I feel comfortable with even one dose, 
but I would agree, let's get two doses in, then in fact, we can start to change how we 
relate to people. If I personally, this is me personally, it is not a public health 
recommendation, there will be those who will be very upset with me because I will 
appear to be undercutting public health and science, but my partner and I both were 
vaccinated and another couple were both vaccinated, I would have a lovely, wonderful 
evening with them at dinner in one of our homes. I would find that to be completely, 
completely safe relative to life itself. Because it can't happen now that I'm going to live 
the rest of my life never being able to or willing to have those kinds of situations again, 
society will just simply not accept that. So what I have urged is that a blue ribbon panel, 
a group like under the support of the CDC somewhere, bring all these issues together 
and say, "How are we going to decide to live with this virus?" Don't tell me that for the 
next 90 days after you've been vaccinated, if you're exposed, you don't have to 
quarantine. OK, tell me then, what is the long term plan? Is it one hundred and twenty 
days? One hundred and eighty days? Well, we're going to get more data. How are we 
going to get more data? When will I know how much data you're going to have? Do I 
have to go to 90 days and hit a cliff and say, "Oh, if I get exposed on day ninety one 
now I got to be quarantined?" We don't have a framework. We don't have a sense of 
what it means to live with this virus. And I understand the frustrations. I understand the 
challenges of people who are now living in this partially vaccinated world, but mostly 
not. And what we need is a game plan. We need a plan. As much as we need a plan for 
testing, we need a plan for vaccinating people. We need a plan for living. And we have 
to raise these challenges, when is it going to be safe enough for us to go back to church 
or to go into other settings? And I'm not even advocating we open it up today. I'm just 
asking the question, what are the criteria we're going to use? How do you unring the 
bell? And the public would even, I think, do much better if they just understood what are 
the goalposts we're going to use? Right now, I feel like, you know, on any one given 
day, we move the goalpost all around the field. And so what do we do if you've had two 
doses of vaccine, does it matter what your age is? What do you do in terms of being in 
public? Understand the political issues of not masking or masking. We've made that 
such a political issue. You know, people's lives have ended because they've been shot 
and killed by somebody who got into an argument about whether they were masked or 
not. Do I suddenly now have a new card with me that says I've had two doses of 
vaccine? What if I am part of that group that doesn't have protection, meaning vaccines 
are ninety, ninety five percent efficacy? Does that mean because of that small group, 
we're never going to let anybody back into the public domain as they once were? What 
happens around the world? When I travel, you know, we know that many countries right 
now are not going to have access to vaccine for a long time, does it matter if what's 
happening now is that one of the variants that defeats the immunity that we have is now 
circulating? Now does that change whether what I do is a vaccinated person actually is 
there? So we need a game plan. We need to get together. We need to have scientists. 
We need to have elected officials. We need to have business people. We need to have 
sixty eight year old grandparents all contributing to that. We need to have teachers. We 
need to have all the people. We need to have the restaurant owners. Let's all get 
together, let's figure out what it is that we want and need and information and decision 
making and then lay out how we're going to get there, then at least I know that 
somebody is going to make a decision. Can I get together with that other couple or not? 
We're all going to start making our own decisions anyway. It would surely be helpful if 
people felt like they had the support of what science we have, and if we don't have the 
science information, how do we collect it? Or if we don't even at this point feel like we 
can collect the information, how are we going to make a decision? And to say when is it 
safe for me to go hug my grandkids? When they all get vaccinated and I get vaccinated, 
what is that? So I know this sounds like I'm rambling, but this is a very emotional 
moment for me in the sense of I feel this pain, I feel this indecision, I feel this confusion. 
And we're at a place right now between the variants making things more complicated, 
between the vaccines as rolling out being exciting and all of us experiencing a year's 
worth of a pandemic that has taken five hundred thousand plus people from us. How do 
we move on? So, you know, we'll help however we can at CIDRAP. We are more than 
willing to put the issues on the table and systematically work through them where I think 
society in general has to be at the table to to help us work on that. So I didn't really 
answer your question other than to say that I am certain that when my partner and I are 
both fully vaccinated and we have dear friends who are both fully vaccinated, no way in 
hell are you going to keep me from not having one of the most wonderful dinners of my 
life with them. I am going to do that. And if that means somehow I did something wrong, 
then I don't know how the rest of the world is going to continue to live with this pandemic 
if we have to believe we can only do things with masks on or we cannot be together 
because we haven't podded. I just think that's not going to work. 
 
Chris Dall: [00:54:24] The wonderful and inspiring pandemic acts of kindness keep 
rolling in from our Osterholm Update listeners, and we have a really nice one this week 
that comes from a listener in Texas, which, as you noted earlier, Mike, had a really, 
really rough week. So can you share with our audience? 
 
Michael Osterholm: [00:54:40] Well, this is one of those very special ones of a mother 
and a daughter. You know, I told you last week, I love when kids get involved, but this is 
an adult daughter. But this is a very, very proud mother and she should be. This is from 
Bonnie. And Bonnie wrote, she said, "Dear Dr. Osterholm, I work at a Texas hospital 
and I did so during the Ebola crisis and thought that would be the defining infectious 
disease of my life. My act of kindness is actually my twenty seven year old daughter's. 
We live near a couple homeless encampments. Last Friday, when my daughter heard 
the temps were going to be dangerously low in Dallas, she got very worried about them. 
She's a marginally employed millennial. So she posted on Facebook that she'd like to 
help but didn't have the means. Her post was very inspirational and before noon on 
Saturday she had sixteen hundred dollars and finally ended up with over two thousand. 
She went to two Wal-Mart and Costcos and bought blankets, socks, hats, scarves, 
sweatshirts, warmers and masks. She distributed them to the encampments and a 
couple of warming stations. She then donated the rest of the money to a church who 
opened their doors to the homeless and a soup mobile. I'm very proud and humbled by 
this extraordinary young woman with a big heart. In this short, long week here in Dallas, 
I'm sure there are people grateful for anything to keep them warm. Bonnie." Bonnie, you 
should be very, very proud of your daughter, and I just bet you, if I could, I think she's, 
as they would say here in the upper Midwest, a chip off the old block. I just suspect that. 
So thank you very much for sharing that incredible act of kindness. I appreciate it more 
than I can tell you, as we do all here at CIDRAP. And again, please keep sending these 
acts of kindness, but most of all, keep doing them. Keep doing them. Be kind, be gentle, 
be kind. 
 
Chris Dall: [00:56:41] And if you want to share your pandemic act of kindness with us, 
please email us at OsterholmUpdate@umn.edu. Your closing thoughts today, Mike. 
 
Michael Osterholm: [00:56:51] Well, we're in a tough time, as I pointed out, we're 
waiting, we're watching and we're waiting. We're watching and we're waiting. And that's 
hard. That's hard. That's real hard. We want to feel the excitement of these case 
numbers dropping that, I must remind you, they're only dropping to levels that are still 
exceeded previous periods when we thought the house was on fire. We want not to 
have to deal with a whole new episode, a surge of of covid cases that could be every bit 
as dangerous as we've experienced already. The vaccines are here. Wait a minute. 
That's not what's supposed to happen. And so I think that from that perspective, it's a 
tough time. And our mental health is wearing down more and more every day. Every 
week. I see it. I feel it. I know it myself personally. So, you know, I decided this week to 
go back and pull out a classic that I think fits the moment. The lyrics for this song that 
I've chosen today, actually was one I used on September 10th in episode twenty three. 
And that title for that week's episode was covid-19 Mental Health. This is a nineteen 
seventy one co-hit, both Carole King included in her Tapestry album and James Taylor 
on his mudslide Slim and the Blue Horizon. You've Got a Friend. As I shared with you 
before, this was a Grammy Award for both Taylor, he received the best male pop vocal 
performance. And for Carole King, she won it for Song of the Year. They each recorded 
the song literally back to back with the same bands. It was a remarkable experience. It's 
one of those ones that for me means so much. In nineteen seventy one when this was 
released was at that time in my life when I was at the very dysfunctional stage in my 
family, as I've shared with you in past podcasts, where my father had been kicked out, 
we were barely getting through it. But I had that LP, Mudslide Slim and The Blue 
Horizon from James Taylor and an old old record player and I can remember day after 
day listening to this. Today, I think it's a good one for us to listen to. It's one that tells us 
we're going to get through this. You've Got a Friend written by Carole King in this case, 
sung by James Taylor. "When you're down and troubled and you need a helping hand 
and nothing no, nothing is going right. Close your eyes and think of me, and soon I will 
be there to brighten up even your darkest nights. You just call out my name and, you 
know, wherever I am, I'll come running. Oh, yeah, baby, to see you again. Winter, 
spring, summer or fall. All you've got to do is call and I'll be there. Yeah, yeah, yeah. 
You've got a friend. If the sky above you should turn dark and full of clouds and that old 
north wind should begin to blow. Keep your head together and call my name out loud 
now, soon I'll be knocking upon your door. You just call out my name and you know, 
wherever I am, I'll come running. Oh, yes, I will. See you again. Winter, spring, summer 
or fall. Yeah. All you got to do is call and I'll be there. Yeah, yeah, yeah. Hey, ain't it 
good to know that you've got a friend. People can be so cold, they'll hurt you and desert 
you well, they'll take your soul if you let them. Oh yeah, but don't let them. Just call out 
my name and, you know, wherever I am, I'll come running to see you again. Oh, baby, 
don't you know about winter, spring, summer or fall? Hey, now all you've got to do is call 
Lord, I'll be there. Yes, I will. You've got a friend. You've got a friend. Yeah, ain't it good 
to know you've got a friend. Ain't it good to know you've got a friend? Oh, yeah yeah. 
You've got a friend." Sally, this one was for you, too. And thank you all so very much, 
we all need friends right now. Be kind and be patient. At the same time, know that it's 
OK to ask tough questions, it's OK right now to feel a sense of disease that you're not 
yet felt. We're at that point in that pandemic where it's just the ability to acknowledge 
that and to know that it's OK. We're all feeling that. But we also can all be friends. And 
that's right now, if there's any act of kindness you can do or anything that will help this 
world find someone this week somehow to be a friend. And it'll make a lot more sense 
out of all this crazy stuff with vaccines and variants and all these other things we deal 
with. Thank you so, so much for spending your time with us. You're very special people. 
Thank you. 
 
Chris Dall: [01:02:20] Thanks for listening to this week's episode of the Osterholm 
Update. If you're enjoying the podcast, please subscribe on your podcast platform of 
choice and write a review. And be sure to keep up with the latest covid-19 news by 
visiting our website CIDRAP.umn.edu. The Osterholm update is produced by Maya 
Peters. Cory Anderson and Angela Ulrich, are our researchers, and Randy and Eric 
Olson are Dr. Osterholm's story consultants. 
 
